Abstract
Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.
Keywords:
cabozantinib; genitourinary malignancies; renal cell carcinoma.
MeSH terms
-
Anilides / chemistry
-
Anilides / pharmacology
-
Anilides / therapeutic use*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Neoplasm Grading
-
Neoplasm Staging
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridines / chemistry
-
Pyridines / pharmacology
-
Pyridines / therapeutic use*
-
Treatment Outcome
-
Urogenital Neoplasms / diagnosis
-
Urogenital Neoplasms / drug therapy*
Substances
-
Anilides
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyridines
-
cabozantinib